Live Cerus fireside chat set for TD Cowen health conference March 3
Cerus Corporation (Nasdaq: CERS) announced that its management will present at the TD Cowen 46th Annual Health Care Conference on March 3, 2026, at 10:30 a.m. EST. A live webcast of the fireside chat will be available on the company's investor relations page, with a replay accessible for 90 days. Cerus is dedicated to blood supply safety, developing pathogen-protected blood components globally.
Cerus Corporation to Release Fourth Quarter and Full-Year 2025 Financial Results on March 2, 2026
Cerus Corporation (Nasdaq: CERS) announced it will release its fourth quarter and full-year 2025 financial results on Monday, March 2, 2026, after market close. The company will also host a conference call and webcast at 4:30 P.M. ET to discuss the results and provide a business overview. Interested parties can access the webcast and presentation slides via the Investor Relations page of the Cerus website.
Cerus sets March 2 date for Q4 and full-year 2025 earnings call
Cerus Corporation (Nasdaq: CERS) announced it will release its fourth quarter and full-year 2025 financial results on Monday, March 2, 2026, after the stock market closes. The company will host a conference call and webcast at 4:30 P.M. ET to discuss the results and provide a business overview and outlook. A replay of the webcast will be available on the Cerus website until March 23, 2026.
Cerus director Timothy L. Moore to step down after 2026 annual meeting
Cerus Corporation announced that director Timothy L. Moore will not seek re-election at the 2026 annual meeting of stockholders, with his current term expiring at that meeting. His decision was not due to any disagreements with the company. This announcement follows recent positive financial news for Cerus, including strong preliminary fourth-quarter product revenue and a new purchasing agreement.
Cerus announces planned board transition as director departs
Cerus Corporation announced that director Timothy L. Moore will not seek re-election at the company's 2026 annual meeting, with his decision not stemming from any disagreements regarding the company's operations. The company's stock, CERS, currently holds a "Hold" rating with a $2.50 price target from analysts, while TipRanks' AI Analyst, Spark, assesses CERS as "Neutral" due to weak financial fundamentals despite a strong uptrend in technicals. The article also highlights ongoing losses, high leverage, deteriorating free cash flow, and overbought signals as contributing factors to its neutral outlook.
Cerus announces planned board transition as director departs
Cerus Corporation announced that director Timothy L. Moore will not seek re-election at the company's 2026 annual meeting, with his departure not stemming from any disagreements. TipRanks' AI Analyst, Spark, rates CERS stock as Neutral due to weak financial fundamentals despite a positive earnings outlook and strong technicals. The stock has a Hold rating from analysts with a $2.50 price target.
New German trial tests safer platelets for cancer patients
Cerus Corporation announced the initiation of the INITIATE study in Germany, led by the German Red Cross Blood Donation Service Baden-Württemberg – Hessen. This multicenter, non-interventional safety study will evaluate the routine use of pathogen-inactivated platelet concentrates using Cerus’ INTERCEPT Blood System in a clinical setting to enhance blood safety, particularly for patients with conditions like leukemia, severe bleeding, or those undergoing chemotherapy. The study aims to gather operational and clinical experience, assess feasibility for broader adoption of pathogen inactivation, and implement recommendations to reduce the risk of transfusion-transmitted infections in Germany.
Sumitomo Mitsui Trust Group Inc. Lowers Stock Holdings in Cerus Corporation $CERS
Sumitomo Mitsui Trust Group Inc. reduced its stake in Cerus Corporation by 6.3% during the third quarter, selling 384,660 shares and holding 5,685,177 shares valued at $9.04 million. Despite this, other hedge funds like AQR Capital Management and Millennium Management increased their positions, with institutional investors and hedge funds collectively owning 78.37% of the stock. Analyst ratings are mixed, resulting in a consensus "Hold" rating and a $4.00 price target, while Cerus's stock saw a 5.1% drop to $2.60.
Cerus (NASDAQ:CERS) Sets New 52-Week High - What's Next?
Cerus (NASDAQ:CERS) shares recently reached a new 52-week high of $2.89, trading up approximately 13.7% with a market capitalization of $550 million. Despite mixed analyst ratings of "Hold" with an average price target of $4.00, the company's Q3 revenue and EPS beat estimates. Institutional investors collectively own about 78% of the stock, with several firms increasing their positions.
Cerus (NASDAQ:CERS) Shares Pass Above 200-Day Moving Average - Should You Sell?
Cerus (NASDAQ:CERS) shares recently traded above their 200-day moving average, reaching $2.13 compared to the average of $1.56, though the stock closed at $2.06. Analyst opinions are divided, with a "Buy" rating from Wall Street Zen and a "Sell" from Weiss Ratings, leading to a consensus "Hold" with an average price target of $4.00. Despite beating revenue and EPS estimates in its last quarterly report, the company remains unprofitable with negative net margin and return on equity.
Analysts Offer Insights on Healthcare Companies: Cerus (CERS) and Kura Oncology (KURA)
Two healthcare companies, Cerus (CERS) and Kura Oncology (KURA), have received bullish sentiments from analysts. TD Cowen analyst Josh Jennings reiterated a Buy rating for Cerus with a $5.00 price target, while TD Cowen analyst Phil Nadeau maintained a Buy rating for Kura Oncology. Both companies show a Street consensus of a Strong Buy rating with average price targets of $4.50 for Cerus and $29.71 for Kura Oncology.
TD Cowen reiterates Buy rating on Cerus stock after strong Q4 results
TD Cowen has reiterated its Buy rating and $5.00 price target for Cerus (NASDAQ:CERS) after the company reported strong preliminary fourth-quarter product revenue of $57.8 million, exceeding consensus estimates, and provided optimistic 2026 revenue guidance. The firm's $5.00 price target represents a significant upside from the current price, aligning with a bullish analyst consensus. Cerus's recent performance is also bolstered by a new group purchasing agreement with Blood Centers of America, expanding its market reach.
Cerus (CERS) Reports Significant Global Expansion of INTERCEPT Blood Components in 2025
Cerus Corporation (CERS) significantly expanded its global reach in 2025, distributing 3 million doses of its INTERCEPT-treated blood components across 40 countries, and anticipates 2026 to be a pivotal year for strategic growth and financial strengthening. Despite a reported 8.5% revenue growth rate, the company faces profitability challenges with negative net and operating margins, and an Altman Z-Score indicating potential financial instability. While analysts have a positive outlook with a target price of $4.67, investors should consider the company's financial health, sector-specific risks, and high stock volatility.
Cerus (CERS) Reports Significant Global Expansion of INTERCEPT Blood Components in 2025
Cerus Corporation (CERS) significantly expanded the global distribution of its INTERCEPT-treated blood components in 2025, reaching 3 million doses in 40 countries. The company anticipates 2026 to be a pivotal year for market expansion and product development, aiming to strengthen its financial standing despite current profitability challenges and financial instability indicated by an Altman Z-Score of -4.21. Investors should consider its poor financial strength and higher stock volatility.
Cerus Corporation Announces Preliminary Fourth Quarter and Full-Year 2025 Product Revenue and Provides Outlook
Cerus Corporation announced preliminary product revenue for Q4 and full-year 2025, with total product revenue increasing by 14% over 2024 to $206.1 million. The company projects 2026 product revenue to be between $224 million and $228 million, reflecting 9%-11% growth, and highlighted key milestones for the upcoming year including PMA submission for INT200 and results from the Phase 3 RedeS study.
Cerus (NASDAQ:CERS) Stock Price Passes Above 200 Day Moving Average - Should You Sell?
Cerus Corporation (NASDAQ:CERS) recently saw its stock price cross above its 200-day moving average, reaching $2.09. Despite beating Q3 revenue and EPS estimates, the company remains unprofitable with mixed analyst ratings. Institutional investors hold a significant portion of the stock, and analysts maintain a "Hold" rating with an average target price of $4.00.
TD Cowen Sees Compelling Long-Term Value in Cerus Corporation (CERS)
TD Cowen sees long-term value in Cerus Corporation (CERS), citing its Intercept Fibrinogen Complex franchise as an "underappreciated" growth engine and a new partnership with Blood Centers of America as a significant booster for adoption and scalability. The firm maintains a 'Buy' rating with a $5 price target, projecting a 143% upside, based on the company's sustainable double-digit revenue growth and appealing valuation. Cerus, a biomedical products company specializing in the INTERCEPT Blood System, recently finalized a purchasing agreement with BCA for its full INTERCEPT product offering.
TD Cowen Sees Compelling Long-Term Value in Cerus Corporation (CERS)
TD Cowen sees Cerus Corporation's Intercept Fibrinogen Complex franchise as an underappreciated growth engine, bolstered by a new BCA partnership. The firm maintains a 'Buy' rating on CERS with a $5 price target, reflecting a potential upside of 143%, confident in the company's double-digit revenue growth and appealing valuation. Cerus Corporation recently signed a purchasing agreement with Blood Centers of America to enhance the adoption of its INTERCEPT product offering and pathogen reduction technology.
Analysts’ Top Healthcare Picks: Cerus (CERS), Entera Bio (ENTX)
This article highlights bullish sentiments from analysts regarding two healthcare companies, Cerus (CERS) and Entera Bio (ENTX). Cerus has a Strong Buy consensus with a significant upside potential, while Entera Bio also received a Buy rating and a strong price target from an analyst. Both analyses come from highly-rated analysts covering the healthcare sector.
Analysts’ Top Healthcare Picks: Cerus (CERS), Entera Bio (ENTX)
Analysts have issued bullish sentiments on two healthcare stocks, Cerus (CERS) and Entera Bio (ENTX). Cerus received a "Strong Buy" consensus with a significant upside potential, while Entera Bio was rated "Moderate Buy" with a $10.00 average price target, reiterated by a 5-star analyst.
Cerus Corporation (NASDAQ:CERS) Stock Catapults 33% Though Its Price And Business Still Lag The Industry
Cerus Corporation's stock has recently surged by 33%, taking its year-long gain to 28%. Despite this momentum, its price-to-sales (P/S) ratio of 2.1x remains below the industry average, which is attributed to an expected future revenue growth of 14% compared to the industry's 58% forecast. This lower P/S suggests investor pessimism regarding Cerus' future financial performance relative to the broader Medical Equipment sector.
Cerus (Nasdaq:CERS) - Stock Analysis
This report provides a comprehensive stock analysis of Cerus Corporation (Nasdaq:CERS), detailing its current market cap of US$413.9m and a share price of US$2.15. The analysis covers valuation, future growth (0/6), past performance (0/6), financial health (5/6), and dividend information, highlighting analyst consensus for a price increase of 117.1%. Despite strong earnings growth over five years and high analyst agreement, the company faces risks such as volatility, unprofitability, and significant insider selling.
Cerus signs purchasing agreement with Blood Centers of America
Cerus Corporation has entered a group purchasing agreement with Blood Centers of America (BCA), the largest blood supply cooperative in the U.S., covering Cerus’s entire INTERCEPT product line. This partnership aims to expand awareness and adoption of pathogen reduction technologies and is expected to provide new customers with access to pathogen-reduced platelets. The agreement follows Cerus's strong Q3 2025 earnings, which surpassed analyst expectations, driven by its INTERCEPT products.
Cerus announces group purchasing pact with Blood Centers of America
Cerus Corporation has signed a group purchasing agreement with Blood Centers of America (BCA), the largest blood supply cooperative in the U.S. This pact covers Cerus's entire INTERCEPT product line, aiming to expand access to pathogen reduction technology for platelets, plasma, and INTERCEPT Fibrinogen Complex across BCA's membership and their hospital customers. The collaboration is expected to drive innovation and the adoption of safer blood products through a resource-sharing model and educational initiatives.
Cerus Corporation Announces Group Purchasing Agreement with Blood Centers of America
Cerus Corporation has entered into a group purchasing agreement with Blood Centers of America (BCA), the largest blood supply cooperative in the U.S. This partnership will expand access to Cerus' INTERCEPT product line, including pathogen reduction technology for platelets, plasma, and INTERCEPT Fibrinogen Complex (IFC), across BCA's network of blood centers. Both organizations are committed to enhancing blood safety and facilitating wider adoption of these critical technologies through resource sharing and educational initiatives.
Cerus Corporation Announces Group Purchasing Agreement with Blood Centers of America
Cerus Corporation announced a new group purchasing agreement with Blood Centers of America (BCA), the largest blood supply cooperative in the U.S. This partnership will expand access to Cerus’ INTERCEPT pathogen reduction technology for platelets, plasma, and cryoprecipitated fibrinogen complex across BCA's network of over 60 independent community blood centers. The agreement also aims to facilitate easier access and distribution of INTERCEPT Fibrinogen Complex (IFC) and pathogen-reduced platelets to hospitals served by BCA members.
Cerus (Nasdaq: CERS) inks BCA deal to expand INTERCEPT blood safety tech access
Cerus Corporation announced a group purchasing agreement with Blood Centers of America (BCA) to expand access to its INTERCEPT product line for pathogen reduction technology. This partnership aims to increase the availability of safer blood products, including pathogen-reduced platelets and INTERCEPT Fibrinogen Complex, across BCA's network of blood centers and their hospital customers. The agreement is expected to facilitate easier distribution and adoption of these critical blood safety technologies.
Promising Penny Stocks To Watch In December 2025
This article identifies promising penny stocks for December 2025, highlighting opportunities for growth despite market volatility and focusing on companies with strong financial resilience. It details specific stocks like CuriosityStream (CURI) and Cerus (CERS), offering an overview of their operations, market capitalization, and financial health, including revenue growth and cash flow. The piece advises investors to consider these smaller companies for potential value, especially given ongoing discussions about interest rate cuts.
Cerus Corporation (NASDAQ:CERS) Stock Catapults 31% Though Its Price And Business Still Lag The Industry
Cerus Corporation's stock has recently surged by 31% in the last month, contributing to a 11% full-year gain, yet its price-to-sales (P/S) ratio of 1.9x remains significantly lower than the industry average, suggesting it may still be undervalued. This low P/S is attributed to expected future revenue growth that lags behind the broader Medical Equipment industry, despite a 26% revenue increase over the last three years. The article concludes that while the recent stock performance is strong, the company's valuation indicates that investors are not expecting substantial future growth without a change in fortune.
Insider Sell: Chrystal Jensen Sells 55,000 Shares of Cerus Corp (CERS)
Chrystal Jensen, Chief Legal Officer at Cerus Corp, sold 55,000 shares of CERS on November 24, 2025, reducing her holdings to 728,294 shares. The company, focused on blood safety technology, is considered "modestly undervalued" with a price-to-GF-Value ratio of 0.79. This transaction follows a pattern of 18 insider sells against 2 insider buys for Cerus Corp over the past year.
Don't Ignore The Insider Selling In Cerus
The Chief Legal Officer of Cerus Corporation, Chrystal Jensen, recently sold stock netting US$94k, reducing her holding by 23%. This sale was the largest insider sale in the past year, and combined with low insider ownership (2.9%), suggests a cautious outlook on the stock. The article advises prudence given the insider selling and limited insider ownership.
Senvest Management LLC Has $5.65 Million Stock Position in Cerus Corporation $CERS
Senvest Management LLC reduced its stake in Cerus Corporation (NASDAQ:CERS) by 9.1% during Q2, selling 400,000 shares but still owning 4,005,568 shares valued at $5.65 million. Despite this, other institutions significantly increased their holdings, leading to institutional investors owning 78.37% of the company. Cerus reported strong Q3 earnings, exceeding revenue and EPS estimates, though it remains unprofitable with analysts forecasting a negative EPS for the year.
Cerus Lifts Revenue Outlook After Beating Wall Street Expectations
Cerus significantly exceeded Wall Street's expectations with a 19% revenue jump in its third quarter, driven by strong demand for its blood technology. The company raised its full-year guidance, expecting 2025 product revenue to reach $204 million. Analysts maintain a "buy" consensus, projecting a 71% upside for the stock.
Cerus Corporation Announces Record Results for Third Quarter 2025 and Raises Full Year 2025 Product Revenue Guidance
Cerus Corporation reported record results for the third quarter of 2025, with total revenue up 19% to $60.2 million and product revenue of $52.7 million, a 15% increase year-over-year. The company has raised its full-year 2025 product revenue guidance to a range of $202 million to $204 million, driven by strong global commercial performance and increasing demand for its INTERCEPT Blood System, including INTERCEPT fibrinogen complex (IFC). Additionally, Cerus completed enrollment in its U.S. RedeS clinical trial for red blood cells, with results expected in the second half of 2026.
Cerus Corporation (NASDAQ:CERS) Q3 2025 Earnings Call Transcript
Cerus Corporation (NASDAQ:CERS) reported its Q3 2025 earnings, showcasing record product revenue of $52.7 million, a 15% year-over-year increase, and achieving its sixth consecutive quarter of positive non-GAAP adjusted EBITDA. The company also raised its full-year 2025 product revenue guidance and discussed the ongoing shift in IFC sales to a kit-based model, which is expected to improve gross margins and leverage existing blood center sales channels. Key updates included continued progress in INTERCEPT adoption, particularly in the US and EMEA, and advancements in its development pipeline with the completion of enrollment in the U.S. Phase III RedeS trial.
Cerus Corporation Announces Record Results for Third Quarter 2025 and Raises Full Year 2025 Product Revenue Guidance
Cerus Corporation announced record financial results for the third quarter of 2025, with total revenue up 19% to $60.2 million and product revenue reaching $52.7 million, a 15% year-over-year increase. The company raised its full-year 2025 product revenue guidance to a range of $202 million to $204 million, driven by strong global commercial performance and increasing demand for its INTERCEPT Blood System. Cerus also reported a narrowed GAAP net loss and positive non-GAAP adjusted EBITDA for the quarter, along with significant progress in its clinical trials.
Cerus Corporation Announces Second Quarter 2025 Financial Results
Cerus Corporation reported strong second quarter 2025 financial results, including record product revenue of $52.4 million, a 16% increase year-over-year. The company raised its full-year 2025 product revenue guidance to $200 million-$203 million, driven by growth in IFC and global platelet sales. Cerus also achieved positive non-GAAP adjusted EBITDA for the quarter and is making progress in its product development pipeline.
Cerus Corporation to Release Third Quarter 2025 Financial Results on November 6, 2025 - Stock Titan
Cerus Corporation announced it will release its third quarter 2025 financial results on November 6, 2025, after the stock market closes. The company will host a conference call and webcast to discuss the results and provide a business overview. Cerus Corporation is dedicated to safeguarding the world's blood supply with its pathogen-protected blood components and INTERCEPT Blood System.
Wealth Enhancement Advisory Services LLC Acquires 27,092 Shares of Cerus Corporation $CERS
Wealth Enhancement Advisory Services LLC has increased its stake in Cerus Corporation (CERS) by acquiring an additional 27,092 shares. Other institutional investors have also adjusted their positions in the biotechnology company, with several firms acquiring new stakes. Cerus Corporation operates as a biomedical products company, focusing on developing and commercializing the INTERCEPT Blood System to enhance blood safety.
Blood Safety Technology Leader Cerus Corp Featured at Major Healthcare Conference - Live Webcast Available
Cerus Corporation announced its participation in the Cantor Global Healthcare Conference 2025, with a fireside chat scheduled for September 3, 2025. A live webcast and replay will be available, highlighting the company's commitment to safeguarding the world's blood supply through its pathogen reduction technologies like the INTERCEPT Blood System. Cerus (Nasdaq: CERS) is a leader in blood safety technology, with products globally approved for platelets and plasma, and other systems under regulatory review or clinical development.
Cerus Corporation (NASDAQ:CERS) Just Reported And Analysts Have Been Cutting Their Estimates
Cerus Corporation (NASDAQ:CERS) recently released its second-quarter results, showing revenues in line with analyst forecasts but larger-than-expected losses. Analysts have subsequently cut their revenue estimates for 2025, although loss per share forecasts have been slightly upgraded. Despite these adjustments, the consensus price target for Cerus remains largely unchanged, indicating analysts believe the business is performing broadly as expected.
Cerus Corporation Announces Additional Department of Defense Award to Advance Care for Major Hemorrhage in Traumatic Injury
Cerus Corporation has received an additional $7.2 million contract amendment from the U.S. Department of Defense to advance the development of lyophilized Pathogen Reduced, Cryoprecipitated Fibrinogen Complex (LyoIFC) for treating traumatic bleeding. This funding will support the CRYO-FIRST randomized study, comparing IFC to conventional cryoprecipitated antihemophilic factor in trauma patients with hemorrhagic shock. The overall goal is to provide a room-temperature, shelf-stable LyoIFC for use in austere environments to improve survival rates in both military and civilian trauma patients.
Cerus Corporation Announces Additional Department of Defense Award to Advance Care for Major Hemorrhage in Traumatic Injury
Cerus Corporation has received an additional $7.2 million contract amendment from the U.S. Department of Defense (DoD) to advance its INTERCEPT Fibrinogen Complex (LyoIFC) for treating traumatic hemorrhage. This funding will support the CRYO-FIRST study, comparing IFC to conventional cryoprecipitate in trauma patients. The goal is to provide a room-temperature, shelf-stable LyoIFC for use in austere military environments and to improve early treatment of fibrinogen deficiency in trauma patients.
Cerus Hits Major Milestone: INTERCEPT Blood System Expands to All Patient Indications in EU Review
Cerus Corporation announced that TÜV-SÜD, their Notified Body, completed the clinical module review for the INTERCEPT Red Blood Cell (RBC) CE Mark submission, transferring information to SÚKL in the Czech Republic. This significant milestone expands the CE Mark submission to include all patient indications for RBC transfusion based on positive Phase 3 ReCePI clinical trial results. The company anticipates continued collaboration with regulatory bodies to finalize the enhanced CE Mark for their INTERCEPT RBC system.
Cerus (NASDAQ:CERS) shareholders have endured a 80% loss from investing in the stock five years ago
Cerus Corporation shareholders have experienced an 80% loss over the past five years and a 20% loss in the last year, despite the company's revenue growing by 16% annually during the five-year period. The market appears concerned about when the company, which is currently operating at a loss, will become profitable. Investors are advised to examine the balance sheet strength and consider potential risks before investing.
Cerus wins regulatory approvals for next-gen blood safety device in France, Switzerland
Cerus Corp. has received regulatory approvals in France and Switzerland for its next-generation blood safety device, the INT200, which enhances the INTERCEPT Blood System with features like touch-screen navigation and improved ergonomics. These approvals, following CE Mark authorization, pave the way for a phased rollout across Europe, the Middle East, and Africa over the next three years, with a U.S. FDA submission anticipated in 2026. The INT200 aims to improve workflow and usability in blood centers, contributing to advancements in blood transfusion safety through pathogen reduction and real-time data integration.
Cerus Corporation Announces Multiple In-Country Regulatory Approvals for INT200 – Next-Generation INTERCEPT Illumination Device
Cerus Corporation has received regulatory approvals in France and Switzerland for its INT200, a next-generation LED-based illumination device designed to enhance blood center operations for the INTERCEPT Blood System. These approvals follow the CE Mark authorization and are an important validation of Cerus's technology, with commercial rollout already underway. The company plans to convert existing INT100s to INT200s in EMEA and pursue further regulatory submissions, including a PMA submission to the FDA during 2026.
Cerus: Q4 Earnings Snapshot
Cerus Corp. reported a Q4 loss of $1.3 million, or 1 cent per share, on revenue of $46.8 million. For the full year, the company's loss narrowed to $37.5 million with revenue reaching $156.4 million. Cerus projects full-year revenue for the upcoming period to be between $172 million and $175 million.
Apheresis Equipment Market Poised for Remarkable Growth: Projected to Reach USD 6.66 billion by 2032 with a Robust 9.0% CAGR | Key Players- Asahi Kasei Corporation, B.Braun SE, Cerus Corporation
The global apheresis equipment market is projected to reach USD 6.66 billion by 2032, growing at a robust CAGR of 9.0% from its 2023 valuation of USD 3.08 billion. This growth is driven by advancements in medical technology, rising prevalence of detrimental illnesses, and increasing demand for blood constituents and therapeutic apheresis procedures. Key players in the market include Asahi Kasei Corporation, B. Braun SE, and Cerus Corporation, with North America currently dominating and Asia Pacific expected to show the fastest growth.
Cerus announces positive results in blood purification trial
Cerus Corporation announced positive topline results from a Phase III clinical trial for its INTERCEPT blood system, designed to protect against pathogens and acute kidney injury during transfusions. The trial showed a 2.5% rate of adverse events among participants, significantly lower than those receiving conventional red blood cells. These results will support a pre-market approval application to the US FDA next year, as the company aims to address the global struggle with blood stock and plasma supply shortages.
